Revisión

Risks and benefits of the new antiepileptic drugs

P. Campos-Olazábal [REV NEUROL 2006;42 (Supl. 3):S57-S60] PMID: 16642453 DOI: https://doi.org/10.33588/rn.42S03.2006031

OPEN ACCESS

Volumen 42 | Number S03 | Nº of views of the article 5.787 | Nº of PDF downloads 2.056 | Article publication date 27/04/2006

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

INTRODUCTION More new antiepileptic drugs (AED) have been introduced over the last decade than in the past 40 years –a fact that has improved our therapeutic capabilities, especially in the case of refractory epilepsies. DEVELOPMENT. The new AED, generally speaking, have a longer half-life, lower rate of protein attachment and a fewer side affects, and interaction takes place to a lesser extent either with other AED and drugs. Yet, paediatric formulations are few, costs are high in developing countries and in such countries their use is often limited by the fact that they are simply not available.

CONCLUSIONS The new AED offer a number of advantages over the classical agents as far as pharmacokinetics and metabolism are concerned, since they do not interact with other medications so frequently. Despite the high economic cost for developing countries, the general impression is that they do indeed reduce the social cost. KeywordsAntiepileptic drugs Epilepsy Social cost of epilepsy CategoriesEpilepsias y síndromes epilépticos

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Revisión

Risks and benefits of the new antiepileptic drugs